| 2026-08-14 | 8-K | Form 8-K, Item 1.01 |
| 2026-08-13 | Press release | OPKO Health Expands Strategic Relationship with HealthCare Royalty Through $125 Million Notes Issuance Secured by Mazdut |
| 2026-07-27 | Press release | OPKO Health Reports Second Quarter 2026 Business Highlights and Financial Results |
| 2026-07-27 | 8-K | Form 8-K, Item 2.02 results |
| 2026-07-27 | 10-Q | Form 10-Q for the quarter ended Jun 30 |
| 2026-07-27 | Transcript | Q2 FY26 earnings call transcript |
| 2026-07-23 | Press release | OPKO Health to Report Second Quarter 2026 Financial Results on |
| 2026-06-18 | 8-K | Form 8-K, Item 5.07 |
| 2026-06-15 | Press release | Preclinical Data for OPKO Biologics' OPK8801001 in Acromegaly Presented at ENDO 2026 |
| 2026-05-12 | Press release | OPKO Health’s ModeX Therapeutics Will Present Data Demonstrating In Vivo CAR-T Cell Generation and Deep B-Cell Depletion |
| 2026-05-08 | Deck | Corporate Presentation |
| 2026-04-30 | Press release | OPKO Health Expands Nicoya Agreement to Support RAYALDEE® Commercialization in Greater China |
| 2026-04-30 | Press release | BioReference® Launches BioReference Direct™, Expanding Access to Consumer-Initiated Diagnostic Testing Through a Fully I |
| 2026-04-30 | Proxy | Definitive proxy statement |
| 2026-04-28 | Press release | OPKO Health Reports First Quarter 2026 Business Highlights and Financial Results |
| 2026-04-28 | Press release | Press release · Q1 2026 · Apr 2026 |
| 2026-04-28 | 8-K | Form 8-K, Item 2.02 results |
| 2026-04-28 | 10-Q | Form 10-Q for the quarter ended Mar 31 |
| 2026-04-22 | Press release | OPKO Health’s ModeX Therapeutics Begins Clinical Trial of Tetraspecific Antibody for Treatment of B-cell Lymphomas |
| 2026-04-21 | Press release | OPKO Health to Report First Quarter 2026 Financial Results on |
| 2026-04-08 | Press release | OPKO Health’s ModeX Therapeutics Initiates Clinical Trial of MDX2301 for the Prevention of COVID-19 |
| 2026-03-19 | 8-K | Form 8-K, Item 5.02 |
| 2026-02-26 | Press release | OPKO Health Reports Fourth Quarter 2025 Business Highlights and Financial Results |
| 2026-02-26 | 8-K | Form 8-K, Item 2.02 results |
| 2026-02-26 | 10-K | Annual report on Form 10-K, FY25 |
| 2026-02-12 | Press release | OPKO Health to Report Fourth Quarter 2025 Financial Results on February 26 |
| 2025-10-29 | Press release | OPKO Health Reports Third Quarter 2025 Business Highlights and Financial Results |
| 2025-10-29 | 8-K | Form 8-K, Item 2.02 results |
| 2025-10-29 | 10-Q | Form 10-Q for the quarter ended Sep 30 |
| 2025-10-22 | Press release | OPKO Health to Report Third Quarter 2025 Financial Results on October 29 |
| 2025-09-15 | 8-K | Form 8-K, Item 7.01 |
| 2025-07-31 | Press release | OPKO Health Reports Second Quarter 2025 Business Highlights and Financial Results |
| 2025-07-31 | 8-K | Form 8-K, Item 2.02 results |
| 2025-07-31 | 10-Q | Form 10-Q for the quarter ended Jun 30 |
| 2025-07-24 | Press release | OPKO Health to Report Second Quarter 2025 Financial Results on July 31 |
| 2025-07-08 | Press release | OPKO Health and Entera Bio Announce Abstract on PK/PD of Oral GLP-2 Tablet for the Treatment of Short Bowel Syndrome Sel |
| 2025-05-29 | 8-K | Form 8-K, Item 5.02 |
| 2025-05-01 | 10-Q | Form 10-Q for the quarter ended Mar 31 |
| 2025-04-30 | Press release | OPKO Health Reports First Quarter 2025 Business Highlights and Financial Results |
| 2025-04-30 | 8-K | Form 8-K, Item 2.02 results |